American Diabetes Association
Supplementary_Material (4).pdf (256.28 kB)

Effects of Tirzepatide Versus Basal Insulins in People with Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials

Download (256.28 kB)
posted on 2024-03-26, 19:02 authored by Francesco Giorgino, Denise R Franco, Claudia Nicolay, Andrea Hemmingway, Ángel Rodríguez, Russell J Wiese

Objective This post hoc analysis assessed change from baseline to Week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3) and glargine (SURPASS-4) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG) and post-prandial glucose (PPG). Research Design and Methods Participant subgroups with low FSG/low PPG, low FSG/high PPG, high FSG/low PPG, and high FSG/high PPG were defined using median values of these measures. Results All tirzepatide doses and basal insulins were associated with decreased HbA1c, FSG, and PPG from baseline to Week 52 in all subgroups (p<0.05). Within each subgroup, HbA1c and PPG decreases were greater with tirzepatide than insulin (p<0.05). FSG decreases were generally similar. There were no differential treatment effects by FSG/PPG subgroup. Conclusions In this post hoc analysis, tirzepatide was associated with superior glycemic control compared to insulin, irrespective of baseline glycemic pattern.


The SURPASS-3 and SURPASS-4 clinical trials and these analyses were funded by Eli Lilly and Company.


Usage metrics

    Diabetes Care


    Ref. manager